A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 27; p. vi350
Main Authors Argiris, A., Gillison, M., Ferris, R.L., Harrington, K., Sanchez, T.K., Baudelet, C., Geese, W.J., Shaw, J., Haddad, R.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.10.2016
Online AccessGet full text

Cover

Author Gillison, M.
Shaw, J.
Harrington, K.
Ferris, R.L.
Sanchez, T.K.
Haddad, R.
Baudelet, C.
Geese, W.J.
Argiris, A.
Author_xml – sequence: 1
  givenname: A.
  surname: Argiris
  fullname: Argiris, A.
  organization: Medical Oncology, Hygeia Hospital, Athens, Greece
– sequence: 2
  givenname: M.
  surname: Gillison
  fullname: Gillison, M.
  organization: Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
– sequence: 3
  givenname: R.L.
  surname: Ferris
  fullname: Ferris, R.L.
  organization: Division of Head and Neck Surgery Departments of Otolaryngology, University of Pittsburgh, Eye and Ear Institute, Pittsburgh, PA, USA
– sequence: 4
  givenname: K.
  surname: Harrington
  fullname: Harrington, K.
  organization: Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK
– sequence: 5
  givenname: T.K.
  surname: Sanchez
  fullname: Sanchez, T.K.
  organization: Global Clinical Research, Oncology, Bristol-Myers Squibb, Princeton, NJ, USA
– sequence: 6
  givenname: C.
  surname: Baudelet
  fullname: Baudelet, C.
  organization: Biostatistics, Bristol-Myers Squibb, Princeton, NJ, USA
– sequence: 7
  givenname: W.J.
  surname: Geese
  fullname: Geese, W.J.
  organization: Oncology, Bristol-Myers Squibb, Lawrence Township, NJ, USA
– sequence: 8
  givenname: J.
  surname: Shaw
  fullname: Shaw, J.
  organization: Clinical Outcomes Assessment and I-O LCM Worldwide Health Economics and Outcomes Research, Bristol-Myers Squibb, Princeton, NJ, USA
– sequence: 9
  givenname: R.
  surname: Haddad
  fullname: Haddad, R.
  organization: Head and Neck Oncology Program, Dana-Farber/Harvard Cancer Center, Boston, MA, USA
BookMark eNp1UcuO1DAQDGiRmF04ceHYRxCbHTsPJ-G2GvGSFnGBc-S0O8Tg2MF2Znf4ejyEKxc_ulxd7qrL7MI6S1n2krMbzrpyL20q4H5W92UjbkT7ONvxWnR5yyp-ke1YV5R5U5fV0-wyhB-MMdEV3e7Ri1vw0io369-krsEtZHMjBzLXsEwyEJQQ4qpO4Eaw-ujMOssBtAV086CtjNpZuNdxAr1oo-e_8DEAPURPM4Gn73omC6-Q4vqgz-gbQB0Wk6h2j9IPbjun-mhW593qJWrzGmSAUfsQc6MtQZzIy-V0ll7Sc7IxbLqecPU-3cF5mCnKEBOOEH6tcnZrACRjIAmhtm6W50FSL5hIKkiTgyX8mR-mtH6WkUDU_Fn2ZJQm0PN_-1X27f27r4eP-d2XD58Ot3c5lgVv80I1Q8s6wbEamqaoRKGwJqFqVRDSKIZSSRrGtulYRU0rpKwr5NiVOHYDZ7y8ytjWF70LwdPYLz455E89Z_051H4Ltd9C7UWbKG83CqV_HTX5PmDyAknp5EPsldP_J_8B4im1Iw
CitedBy_id crossref_primary_10_1002_hed_24986
crossref_primary_10_3390_ijms241411695
crossref_primary_10_3390_cancers14204985
crossref_primary_10_3390_cancers11040472
crossref_primary_10_3390_cancers12113358
crossref_primary_10_1016_j_clim_2021_108873
crossref_primary_10_1080_14728214_2020_1852215
crossref_primary_10_37349_etat_2021_00062
crossref_primary_10_1186_s40425_019_0662_5
crossref_primary_10_21164_pomjlifesci_571
crossref_primary_10_5106_jjshns_28_313
crossref_primary_10_5306_wjco_v13_i5_388
ContentType Journal Article
Copyright 2016 European Society for Medical Oncology
Copyright_xml – notice: 2016 European Society for Medical Oncology
DBID 6I.
AAFTH
AAYXX
CITATION
DOI 10.1093/annonc/mdw376.68
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
DatabaseTitle CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1569-8041
EndPage vi350
ExternalDocumentID 10_1093_annonc_mdw376_68
S0923753419446437
GroupedDBID ---
-E4
.2P
.86
.I3
.XZ
.ZR
08P
0R~
1TH
23M
2WC
4.4
482
48X
53G
5GY
5VS
5WA
6.Y
6I.
6J9
70D
AABJS
AABMN
AAEDW
AAESY
AAFTH
AAIAV
AAIYJ
AAJKP
AAJQQ
AAKAS
AAKUH
AAMVS
AAOGV
AAPNW
AAXUO
ABEUO
ABIXL
ABJNI
ABKDP
ABLJU
ABNKS
ABOCM
ABQLI
ABVKL
ABZBJ
ACGFO
ACGFS
ACIMA
ACPRK
ACUFI
ACUTO
ADBBV
ADEIU
ADEYI
ADHKW
ADHZD
ADJQC
ADOCK
ADORX
ADQLU
ADRIX
ADRTK
ADYVW
ADZCM
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AEWNT
AFIYH
AFOFC
AFXEN
AGINJ
AGKEF
AGSYK
AHMBA
AHXPO
AIAGR
AIJHB
AIKOY
AITUG
ALMA_UNASSIGNED_HOLDINGS
ALUQC
AMRAJ
APIBT
APWMN
ASMCH
AWCFO
AXUDD
AZQFJ
BAWUL
BAYMD
BEYMZ
BGYMP
BHONS
BTRTY
BVRKM
CASEJ
CDBKE
CKLRP
COF
CS3
CZ4
DAKXR
DIK
DILTD
DPORF
DPPUQ
D~K
E3Z
EBS
EE~
EJD
F9B
FDB
GJXCC
GX1
H5~
HAR
HW0
HZ~
I09
IH2
IOX
J21
KAQDR
KOM
KOP
KQ8
KSI
KSN
M-Z
M41
M49
MHKGH
N9A
NCXOZ
NGC
NOYVH
NU-
NVLIB
O9-
OAWHX
ODMLO
OJQWA
OK1
OVD
P2P
P6G
PAFKI
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
ROL
ROX
RW1
RXO
TCURE
TEORI
TJX
TR2
W8F
WOQ
X7H
YAYTL
YFH
YKOAZ
ZKX
~91
0SF
0U7
AALRI
AAUQX
AAYXX
ABQTQ
ABSAR
ABSMQ
ACMRT
ACPQN
ADVLN
AEHUL
AEKPW
AFETI
AFJKZ
AFSHK
AGKRT
AKRWK
AQKUS
ASPBG
ATTQO
AVWKF
AZFZN
BGNMA
BZKNY
C1A
CAG
CITATION
DL5
EX3
FEDTE
H13
HVGLF
IHE
KC5
KDC
LAK
M4Y
MBLQV
NTWIH
NU0
PB-
QBD
RNI
ROZ
RPX
RZC
RZE
RZF
RZO
SDH
TMA
U2A
WOW
ZXP
ID FETCH-LOGICAL-c3218-2d7b80961c4b772462dc5e6d5d2ecef6b3daebf87904e786aa54c1c93cf9b1013
IEDL.DBID ABVKL
ISSN 0923-7534
IngestDate Thu Sep 26 17:54:07 EDT 2024
Fri Feb 23 02:47:05 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License http://www.elsevier.com/open-access/userlicense/1.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3218-2d7b80961c4b772462dc5e6d5d2ecef6b3daebf87904e786aa54c1c93cf9b1013
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S0923753419446437
ParticipantIDs crossref_primary_10_1093_annonc_mdw376_68
elsevier_sciencedirect_doi_10_1093_annonc_mdw376_68
PublicationCentury 2000
PublicationDate 2016-10-01
2016-10-00
PublicationDateYYYYMMDD 2016-10-01
PublicationDate_xml – month: 10
  year: 2016
  text: 2016-10-01
  day: 01
PublicationDecade 2010
PublicationTitle Annals of oncology
PublicationYear 2016
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
SSID ssj0006929
Score 2.28627
SourceID crossref
elsevier
SourceType Aggregation Database
Publisher
StartPage vi350
Title A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651
URI https://dx.doi.org/10.1093/annonc/mdw376.68
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwEDbLroS4IFhALC_NgQMr1jRNHCc5lorVCuhygEUVl8hPrUWblKbl9euZiVMEEly4JJEtx3bGmfnG45lh7InK00TJTPJKJ5aLsU95lbuUS-e1zktjpSd_59m5PLsQr-b5fI9Nd74wdKxy4P2Rp_fceigZDV9ztAph9C5BbIJgW6AaLsj8dJUdpIh-8e88mLz48PrNL4YsqzSG3EszTg0GayXq8pTrpW0MKv9f8Ud7TvFW_yadfpM4pzfZjQEqwiSO5hbbc80huzYbjOG3rxxOAAWNbZfhh7MnQHmwONLULU5gdYnCCTLog8dC66EJPRtSGkIDOFfUh3uSAO3DQliFRVj21V86QHZNm4ZAORuWroGnxm223wLVPgMTuhUdn2tGRq11G5-x3C-27RpHrExYHIPqwAfElZxALEQfr-_U9RDGtYv9rmmzn8JDQbuGpdsocm8KBrrPW0VbEkBmBTCU7qhpl4omgu8ClB8WcObQOPOJTy_xOkPIDDIf32EXpy_fT8_4kOOBmwzRBU9toUtKO2OERqAvZGpN7qTNbeqM81JnVjnty6JKhCtKqVQuzNhUmfGVRnaS3WX7SEJ3j4FF1SgxqJ5aIUTqRVW4IiuMq7wtrZH-iB3vaFuvYiiPOprgszqugzqug1qWRyzbEb_-YznWKGn-2er-f7V6wK4jCpPxhOBDtr9Zb90jRDob_XhYyXg_n87ffvwJcYQIJg
link.rule.ids 315,783,787,27581,27936,27937,45675
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwEDZLVwIuCBYQy3MOHFixpmniOMmxVKwK2-6FXbS3yE-tRZuUPnj9embqFIEEFy5RZMuJnZnMfDNjzzD2QuVpomQmeaUTy8XAp7zKXcql81rnpbHS03nn6ZkcX4j3l_nlHhvtzsLQtspO9keZvpXWXUu_-5r9RQj9DwliEwTbAs1wQeGn62wf0UCR99j-8M3H08kvgSyrNKbcSzNOA7poJdryVOulbQwa_1_xR3tN-Vb_pp1-0zgnd9jtDirCMM7mLttzzQG7Me2C4feuHQwBFY1t5-GHs8dAdbA40tTNjmFxhcoJMtgmj4XWQxO2YkhpCA3gWtEe3pIEyA8LYRFmYb7t_rICFNfkNASq2TB3Dbw0br35Fqj3FZiwWtD2uaZv1FK38R7b_WzTLnHGyoTZEagV-IC4khOIhXjG6zu9ukvjuorvXZKzn9JDQbuEuVsrOt4UDKw-bxS5JIDCCmCo3FHTzhUtBJ8FqD8s4MqhceYTH13hdYqQGWQ-uM8uTt6ej8a8q_HATYbogqe20CWVnTFCI9AXMrUmd9LmNnXGeakzq5z2ZVElwhWlVCoXZmCqzPhKozjJHrAektA9ZGDRNEoMmqdWCJF6URWuyArjKm9La6Q_ZEc72taLmMqjjiH4rI58UEc-qGV5yLId8es_2LFGTfPPUY_-a9RzdnN8Pp3Uk3dnp4_ZLURkMu4WfMJ66-XGPUXUs9bPOq7-CbEBCV8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+randomized%2C+open-label%2C+phase+3+study+of+nivolumab+in+combination+with+ipilimumab+vs+extreme+regimen+%28cetuximab+%2B+cisplatin%2Fcarboplatin+%2B+fluorouracil%29+as+first-line+therapy+in+patients+with+recurrent+or+metastatic+squamous+cell+carcinoma+of+the+head+and+neck-CheckMate+651&rft.jtitle=Annals+of+oncology&rft.au=Argiris%2C+A.&rft.au=Gillison%2C+M.&rft.au=Ferris%2C+R.L.&rft.au=Harrington%2C+K.&rft.date=2016-10-01&rft.issn=0923-7534&rft.volume=27&rft.spage=vi350&rft_id=info:doi/10.1093%2Fannonc%2Fmdw376.68&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_annonc_mdw376_68
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0923-7534&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0923-7534&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0923-7534&client=summon